Investigational drug · Phase 2
RGT001-075
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity or Overweight.
Phase 2Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "RGT001-075"
First trial start
2025
Jan 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RGT001-075", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity or Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "RGT001-075" as an intervention, largest first.
- Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health ConditionsPivotal-lookingCompleted
Regor Pharmaceuticals Inc.Industry
NCT06867718 · 267 participants · Start Jan 24, 2025 · Primary completion Nov 6, 2025
Drug: RGT001-075; Placebo Comparator · For: Obesity or Overweight
Sites: Mobile, Alabama; Phoenix, Arizona; Huntington Park, California · 35 sites in all
- A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related ComorbiditiesCompleted
Regor Pharmaceuticals Inc.Industry
NCT06277934 · 73 participants · Start Mar 8, 2024 · Primary completion Aug 13, 2024
Drug: RGT001-075; Placebo · For: Obesity
Sites: Los Angeles, California; Valparaiso, Indiana; Omaha, Nebraska · 10 sites in all
Regor Pharmaceuticals Inc.Industry
NCT05297045 · 17 participants · Start Mar 29, 2022 · Primary completion May 30, 2023
Drug: RGT001-075 · For: Type 2 Diabetes Mellitus
Sites: Doral, Florida
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity or Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- AZD5004Phase 22 trials
AstraZeneca · Obesity or Overweight, Diabetes Mellitus, Type 2
- TifeglipronRO7795081, CT-996Phase 22 trials
Roche (Genentech) · Type 2 Diabetes Mellitus, Obesity or Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.